Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Sjögren's Syndrome with Inflammatory Arthritis
NCT02027298Phase 2Withdrawn
- Sponsor
- Cleveland Clinic
- Start
- Nov 2013
- Primary completion
- Oct 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in Sjögren's syndrome and inflammatory arthritis, sponsored by Cleveland Clinic. Primary endpoint: Efficacy of Abatacept in patients with inflammatory arthritis and Sjogren's Syndrome at 6 months. Planned start Nov 2013; status: withdrawn.
02
Drugs
abatacept
03
Conditions
Sjögren's syndromeinflammatory arthritis
Beyond the preview
Go deeper on NCT02027298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027298.